ABI Sues Stratagene in Europe for Allegedly Infringing qPCR Patent | GenomeWeb
NEW YORK (GenomeWeb News) — Applied Biosystems' parent company has sued Stratagene in the Netherlands and France for allegedly infringing an ABI patent, Stratagene said in a filing with the US Securities and Exchange Commission yesterday.
 
According to the filing, on May 23 Stratagene received a writ of summons filed by Applera in the District of The Hague in the Netherlands alleging that Stratagene's Mx3000P, Mx3005P, Mx4000P, and "certain related reagents" infringe ABI’s EU patent No. 0 872 562 B1.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.